

Appl. No. 09/489,667
Reply to Office Action of October 24, 2005

BEST AVAILABLE COPY

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-68. (Cancelled)

69. (Currently amended) An agent for treating pain comprising a modified elestridial botulinum neurotoxin comprising a botulinum neurotoxin H_N, a botulinum neurotoxin L chain, and no functional H_C domain, wherein the modified elestridial neurotoxin is obtained by removing or modifying an HC domain of a native elestridial neurotoxin to form an intermediate elestridial neurotoxin and covalently coupling the modified botulinum neurotoxin being covalently coupled to substance P to the intermediate elestridial neurotoxin so that the modified elestridial botulinum neurotoxin no longer binds to botulinum neurotoxin receptors at a neuromuscular junction with the same affinity as the native elestridial botulinum neurotoxin.

70. (Cancelled)

71. (Currently amended) The agent of claim 69 wherein the elestridial botulinum neurotoxin is a botulinum toxin selected from the group consisting of serotype A, serotype B, serotype C₁, serotype D, serotype E, serotype F and serotype G.

72. (Currently amended) The agent of claim 69 wherein the elestridial botulinum neurotoxin is botulinum toxin serotype A.

Appl. No. 09/489,667
Reply to Office Action of October 24, 2005

BEST AVAILABLE COPY

73. (Currently amended) The agent of claim 69 wherein the ~~clostridial botulinum neurotoxin comprises an H_N and an L chain~~ agent is a fusion protein.

74. (Cancelled)

75. (Currently amended) The agent of ~~claim 73~~ wherein the L chain is obtained from an organism selected from the group consisting of ~~Clostridial beratti, Clostridial butyricum, Clostridial botulinum, and Clostridial tetani~~ claim 69, wherein the L chain is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C₁, serotype D, serotype E, serotype F and serotype G.

76. (Currently amended) The agent of ~~claim 73~~ claim 69, wherein the H_N is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C₁, serotype D, serotype E, serotype F and serotype G.

77. (Previously presented) An agent for treating pain comprising a botulinum toxin, without an H_c that binds to receptors at the neuromuscular junction with the same affinity as native botulinum toxin, covalently coupled to substance P.

78. (Previously presented) An agent for treating pain comprising a botulinum toxin serotype A, without a functional H_c domain, covalently coupled to substance P.

BEST AVAILABLE COPY

Appl. No. 09/489,667
Reply to Office Action of October 24, 2005

79. (Previously presented) An agent for treating pain comprising a botulinum toxin covalently coupled to substance P, wherein an H_c of the toxin has been removed.

80. (Previously presented) An agent for treating pain comprising a botulinum toxin serotype A covalently coupled to substance P, wherein an H_c of the toxin has been removed, the agent treats pain by acting on a projection neuron.